Online citations, reference lists, and bibliographies.
← Back to Search

Single-agent Treatment With Pegylated Liposomal Doxorubicin For Metastatic Breast Cancer

M. O'Brien
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Anthracyclines and taxanes are among the most active substances used in the treatment of metastatic breast cancer (MBC). Their frequent use in the adjuvant setting and in cumulative toxicities including cardiotoxicity, however, often limit their use in MBC. The trend towards the use of adjuvant trastuzumab-containing regimens, which can also produce cardiotoxicity, adds further support to the need for effective agents with improved tolerability in the metastatic setting. Pegylated liposomal doxorubicin (PLD) can be an effective alternative to conventional anthracyclines for certain women with MBC. In phase III clinical trials, PLD was as effective as doxorubicin and produced significantly less cardiotoxicity in women with MBC. The incidences of myelotoxicity, nausea/vomiting, and alopecia were also lower with PLD, whereas hand–foot syndrome and stomatitis occurred more frequently. Phase II and III trials conducted in women with MBC support the use of PLD monotherapy in patients relapsing after adjuvant anthracycline-containing therapy, in heavily pretreated patients with taxane-refractory disease, in patients with cardiovascular risk factors (e.g. hypertension and mediastinal irradiation), in elderly patients, and in patients for whom specific acute doxorubicin toxicities, such as alopecia, are particularly worrying.
This paper references
10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Z. Symon (1999)
10.7748/CNP.4.1.6.S6
The 27th annual San Antonio breast cancer symposium
R. Short (2005)
Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
A Gabizon (2003)
10.1200/JCO.1997.15.10.3185
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
10.1016/S0002-9629(15)40798-0
Doxorubicin-induced cardiomyopathy.
F. Otero (2000)
10.1007/s00280-001-0405-3
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
E. Rivera (2001)
for the 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
S Chan (1999)
10.1016/J.EJCA.2005.12.011
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
10.1056/NEJMOA054504
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
K. Pritchard (2006)
10.1007/BF00685327
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
B. Conley (2004)
10.1200/JCO.2005.03.8331
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo
C Kim (2005)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1200/JCO.2004.08.157
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
Innovations in anthracycline therapy: overview
JT Thigpen (2005)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
S Chan (1999)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.1200/JCO.2001.19.14.3439
Developing drugs to decrease the toxicity of chemotherapy.
G. Williams (2001)
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
V. Pai (2000)
Anthracycline-induced cardiotoxicity and its relevance in cancer treatment
C Praga (1991)
10.1186/bcr432
Liposome-based drug delivery in breast cancer treatment
J. Park (2002)
10.1038/sj.bjc.6603158
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S. Al-Batran (2006)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer
R E Coleman
National Comprehensive Cancer Network website . Clinical practice guidelines in oncology : breast cancer v . 2 . 2006
MR Ranson
10.1053/J.SEMINONCOL.2004.09.018
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
N. Robert (2004)
10.3892/OR.12.3.549
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
M. Orditura (2004)
10.1200/JCO.1999.17.8.2341
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)
10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
10.1053/J.SEMINONCOL.2004.08.002
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
D. Vail (2004)
Clinical practice guidelines in oncology: breast cancer v
10.1159/000080363
Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure
B. Mlineritsch (2004)
10.1200/JCO.1998.16.11.3502
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
M. Ryberg (1998)
Phase II randomized trial of pegylated liposomal doxorubicin versus weekly docetaxel with subsequent crossover as first-line chemotherapy for metastatic breast cancer
DA Yardley (2004)
10.1634/THEONCOLOGIST.10-3-205
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
P. Rose (2005)
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity
M Orditura
10.1053/J.SEMINONCOL.2004.08.001
Advantages of liposomal delivery systems for anthracyclines.
T. Allen (2004)
10.1200/JCO.2007.25.18_SUPPL.1007
Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study
E. Alba (2007)
10.1159/000093005
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)



This paper is referenced by
10.1038/cgt.2017.9
The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials
L. Ansari (2017)
10.1186/1471-2407-10-2
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
J. Huober (2009)
10.1111/j.1524-4741.2010.00911.x
Overcoming Taxane and Anthracycline Resistance
A. Zelnak (2010)
10.1517/13543776.2012.661413
5-Fluorouracil derivatives: a patent review
P. Álvarez (2012)
10.2165/11207510-000000000-00000
Pegylated Liposomal Doxorubicin
S. Duggan (2012)
10.3109/02656731003639364
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
Z. Vujasković (2010)
Characterisation of TRAIL Receptor Signalling To Apoptosis in Pre-clinical Models of Breast Cancer
Shambhavi Naik (2011)
10.1115/1.3081394
Optimization of Plasma Treatment, Manipulative Variables and Coating Composition for the Controlled Filling and Coating of a Microstructured Reservoir Stent
M. Mekki (2009)
10.1038/sj.bjc.6604409
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
V. Adamo (2008)
10.1007/978-3-662-43604-2_6
Metronomic Chemotherapy in Breast Cancers
E. Munzone (2014)
10.1117/12.909071
Delayed photolysis of liposomes: a strategy for the precision timing of bolus drug release using ex-vivo photochemical sensitization
Raymond T. Kozikowski (2012)
10.1038/gt.2008.79
Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice
D. Kim (2008)
10.1111/tbj.12975
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long‐term results from a single institution experience
P. Martin-Romano (2018)
10.1021/bm9009667
PGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucin.
P. Griffiths (2010)
10.1038/nrd2614
Nanoparticle therapeutics: an emerging treatment modality for cancer
M. Davis (2008)
10.1038/nrclinonc.2015.131
Clinical overview of metronomic chemotherapy in breast cancer
E. Munzone (2015)
10.1016/J.JAB.2015.11.002
Extracorporeal apheresis system – A nanoparticle drugs’ elimination method to enhance the benefit of cytostatic therapy in cancer patients
S. Filip (2016)
10.1016/j.breast.2009.10.003
Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
E. Munzone (2010)
This information is current as Encephalomyelitis of Experimental Autoimmune TreatmentAlters Their Mode of Action in the Liposomal Encapsulation of Glucocorticoids
Fred Lühder (2011)
10.3816/CBC.2008.S.002
Options for the treatment of patients with taxane-refractory metastatic breast cancer.
B. Overmoyer (2008)
10.1093/annonc/mdq080
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
E. Chuang (2010)
10.4049/jimmunol.1101604
Liposomal Encapsulation of Glucocorticoids Alters Their Mode of Action in the Treatment of Experimental Autoimmune Encephalomyelitis
N. Schweingruber (2011)
The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin.
Hussein Rastegar (2013)
10.1007/978-2-8178-0076-9_19
Récidive homolatérale des cancers du sein : quels traitements adjuvants systémiques ?
H. Curé (2010)
10.1038/s41598-020-75614-4
Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin
S. Szmit (2020)
10.1016/j.healun.2009.06.025
Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
A. Goetzenich (2009)
10.1179/joc.2011.23.3.158
Pegylated Liposomal Doxorubicin (Caelyx®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines
L. Livi (2011)
10.1016/j.ijpharm.2008.08.005
Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells.
R. Schiffelers (2008)
10.1016/j.jconrel.2009.08.002
Real-time electrochemical monitoring of drug release from therapeutic nanoparticles.
L. Mora (2009)
Uptake and intracellular trafficking of nanoparticles for potential medical use
Lettiero (2011)
10.1186/s12885-015-1433-4
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
K. Rau (2015)
10.1530/ERC-13-0439
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
C. Hantel (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar